COVID-19

Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates

Topline results from planned Phase 2 trial of AVTX-009 in hidradenitis suppurativa expected in 2026Cash on hand of approximately $110…

4 weeks ago

Tevogen Bio Announces Up to $50 Million in Financing to Further Advance Operational Objectives

Supports expansion of Tevogen’s ExacTcell™ platform toward additional clinical trialsBolsters a financial path to positive cashflow and minimizes dilution WARREN, N.J.,…

1 month ago

Evaxion Receives Nasdaq Notification

COPENHAGEN, Denmark, May 10, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio…

1 month ago

Atrion Reports First Quarter 2024 Results

ALLEN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Atrion Corporation (NASDAQ: ATRI) today announced its results for the first quarter…

1 month ago

Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results

STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),…

1 month ago

Hyperfine, Inc. to Expand Global Market Reach with Appointment of International Distributors in Key European Markets

- Distributors appointed in France, the United Kingdom, and Italy - Industry veteran Enrico Barini joins as International Business Development…

1 month ago

Applied DNA Regains Compliance with Nasdaq Minimum Bid Price Requirement

STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) (Applied DNA), a leader in…

1 month ago

Moderna Announces Update on Investigational RSV Vaccine

U.S. FDA has informed Moderna that due to administrative constraints, the agency will not complete its review of mRNA-1345 by…

1 month ago

NanoViricides to Participate in the 2024 EF Hutton Annual Global Conference On May 15 in New York City

SHELTON, CT / ACCESSWIRE / May 10, 2024 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a global leader in broad-spectrum…

1 month ago

Checkpoint Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Updates

WALTHAM, Mass., May 10, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology…

1 month ago